Troluce Capital Advisors LLC T Scan Therapeutics, Inc. Transaction History
Troluce Capital Advisors LLC
- $1.35 Billion
- Q3 2024
A detailed history of Troluce Capital Advisors LLC transactions in T Scan Therapeutics, Inc. stock. As of the latest transaction made, Troluce Capital Advisors LLC holds 52,914 shares of TCRX stock, worth $213,243. This represents 0.02% of its overall portfolio holdings.
Number of Shares
52,914
Previous 92,832
43.0%
Holding current value
$213,243
Previous $543,000
51.57%
% of portfolio
0.02%
Previous 0.07%
Shares
2 transactions
Others Institutions Holding TCRX
# of Institutions
89Shares Held
41.8MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR5.22MShares$21.1 Million9.31% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5MShares$20.2 Million1.08% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$18 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA4.4MShares$17.7 Million0.04% of portfolio
-
Bvf Inc San Francisco, CA2.99MShares$12 Million0.47% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $76.3M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...